Trial Profile
Phase II open label study to establish the safety and efficacy of intravenous loading dose of ibandronate [ibandronic acid] 6 mg in 3 consecutive days in breast cancer patients with skeletal metastases
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Advanced breast cancer; Cancer metastases
- Focus Therapeutic Use
- 07 Nov 2006 Status change
- 14 Oct 2006 New trial record.